Clinical Trial Update: Ruxolitinib Plus LVP in Patients With R/R ETP-ALL [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ruxolitinib plus LVP in relapsed/refractory early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) spanning Phase 1 and Phase 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cell Leukemia

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Sichuan University | Conditions: Acute T Cell Leukemia | Phase 1, Phase 2 | Status: UNKNOWN